Therapeutic effect of apatinib monotherapy on recurrence and persistent cervical squamous cell carcinoma due to failure of chemoradiotherapy or other targeted therapy and correlation research between the efficacy of apatinib and the angiogenesis immune response subtype gene
Latest Information Update: 26 Sep 2019
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 26 Sep 2019 New trial record